{"id":"W4405126145","doi":"10.1182/blood-2024-205666","title":"A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO - a Report from the Children's Oncology Group","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hospital for Sick Children","funders":"Servier; Astellas Pharma; Syndax Pharmaceuticals; Incyte; Jazz Pharmaceuticals; Celgene","keywords":"Gemtuzumab ozogamicin; Medicine; Oncology; Internal medicine; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002881586,0.002375728,0.003015646,0.0005764068,0.0004736109,0.001224904,0.001236484,0.00219602,0.009108119],"category_scores_gemma":[0.002401804,0.0007595059,0.002098222,0.0004753366,0.001477454,0.001424551,0.0006719685,0.004324466,0.001315378],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001087848,"about_ca_system_score_gemma":0.001892245,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008973766,"about_ca_topic_score_gemma":0.00171987,"domain_scores_codex":[0.9990041,0.0005929724,0.00004119606,0.0001725061,0.00005410748,0.0001351884],"domain_scores_gemma":[0.9979401,0.0006291281,0.0004323617,0.0001847212,0.00007924647,0.0007345128],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9897227,0.003895196,0.0003905146,0.0001057073,0.0002962952,0.0000234687,0.00002332734,0.0002031412,0.0009886839,0.00009873035,0.000550058,0.003702078],"study_design_scores_gemma":[0.9549144,0.04286736,0.000916191,0.0000118657,0.0001402859,0.0000226518,0.000009656633,0.0003849563,0.0001666639,0.0001969109,0.0003612557,0.000007795436],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9800783,0.002056822,0.0008236272,0.002023627,0.001041392,0.008909215,0.001900179,0.0002043597,0.002962572],"genre_scores_gemma":[0.9764213,0.00105391,0.002648606,0.002732909,0.0008122116,0.009873724,0.002093121,0.00004169016,0.004322621],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009108119,"threshold_uncertainty_score":0.03046972,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01749470687045951,"score_gpt":0.3249208257903451,"score_spread":0.3074261189198856,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}